PIK3CA and Hyperglycemia: In terms of adverse events, the incidence of grade ≥3 events was significantly increased in the PI3K inhibitors combined with fulvestrant group (RR=2.11, 95% CI: 1.73-2.58, P<0.0001), particularly hyperglycemia, rash, and transaminitis (ALT).